Long- term outcome of thalidomide and cyclosporine in patients with IPSS low/intermediate- 1 myelodysplastic syndromes / 中华血液学杂志
Chinese Journal of Hematology
;
(12): 942-946, 2015.
Artigo
em Chinês
| WPRIM
| ID: wpr-296114
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the long- term outcome of cyclosporin A (CsA) combined with thalidomide regime for Chinese patients with IPSS low/intermediate- 1 myelodysplastic syndromes (MDS) without del(5q)and the predictive variables which could impact the response to the therapy.</p><p><b>METHODS</b>Seventy-six MDS patients who were treated with these drugs at a single institute in China were retrospectively analyzed. The polymorphism of cereblon gene, rs1672753, was detected in patients of this cohort by PCR and direct sequencing.</p><p><b>RESULTS</b>A total of 53% of patients showed hematological improvement(HI)to the therapy. Thirty-one patients(31/73, 43%)achieved erythrocyte response(HI-E); 15 patients(15/50, 30%)achieved neutrophil response(HI-N); 18 patients(18/58, 31%)achieved platelet response(HI-P). Twenty-seven of the 50 patients(46%)who were dependent on red blood cell transfusion achieved HI- E and became independent of transfusion. The median duration of response among the responders was 22 months (range, 1- 131 + months). Bone marrow blasts ≤2% was the only factor associated with longer response duration in univariate analysis (P=0.010). There was no significant difference between the two groups of celeblon gene rs1672753 polymorphism either on the response rate or the response duration. The median survival of 67 patients without stem cell transplantation was 82 months. In multivariate analyses, factors significantly correlated with survival were IPSS-R(HR=3.461, 95%CI 1.126-10.639, P=0.030), age ≥ 60 y(HR=4.120, 95%CI 1.070-15.867, P=0.040)and HI-N(HR=7.733, 95%CI 1.007-59.396, P=0.049).</p><p><b>CONCLUSION</b>CsA combined with thalidomide regime could improve the anemia symptom in low/int-1 risk MDS patients without del(5q). The predictive value of cereblon gene polymorphism, rs1672753, could not be verified in this study.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Peptídeo Hidrolases
/
Talidomida
/
Plaquetas
/
Transfusão de Sangue
/
Medula Óssea
/
Síndromes Mielodisplásicas
/
Indução de Remissão
/
China
/
Estudos Retrospectivos
/
Resultado do Tratamento
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Limite:
Humanos
País/Região como assunto:
Ásia
Idioma:
Chinês
Revista:
Chinese Journal of Hematology
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS